Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04501562 |
| Other study ID # |
2019/2252 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 13, 2019 |
| Est. completion date |
December 2049 |
Study information
| Verified date |
March 2023 |
| Source |
National Heart Centre Singapore |
| Contact |
Angela Koh, M.D. |
| Phone |
67042228 |
| Email |
angela.koh.s.m[@]singhealth.com.sg |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Specific Aim 1: To determine longitudinal changes in CV ageing (changes in CV imaging) over
time.
Hypothesis: There are differences in rates of CV ageing over time.
Specific Aim 2: To study determinants of CV ageing To assess how biological pathways affect
CV ageing by studying the relationships between biological signatures measured in
longitudinal biospecimens are associated with CV ageing.
Hypothesis: Antecedent biological markers are associated with progression of CV ageing.
Specific Aim 3: To determine the impact of CV ageing progression on the development of
clinical CVD and the overall physical, cognitive and functional health of the elderly.
Hypothesis: Those with stable CV imaging phenotypes have lower incidence of clinical CVD and
also better overall health in ageing, compared to those with rapid deterioration (unhealthy
CV ageing).
Description:
In Singapore, elderly residents aged 65 years and above make up 10.5% of our population and
this is expected to double in 2030 (Singapore Department of Statistics, Ministry of Manpower,
Registry of Birth and Deaths, September 2014). Cardiovascular diseases account for the
majority of disability-adjusted life years by broad cause group, accounting for 20% of
399,675 life years lost due to mortality and ill-health in 2010 (Source: Estimates from the
Singapore Burden of Disease Study 2010).
While chronological ageing is inevitable, a clear understanding is needed as to how ageing
becomes a critical risk component of CVD for some individuals, and the mechanisms through
which ageing results in such a vulnerable phenotype that leads towards clinical CVD.
Following that, clinical tools and clinical guidelines to reduce cardiovascular disease and
other health burdens contributed by ageing may be formulated. Such strategies may potentially
reduce burdens and cost of healthcare provision to the ageing population.
Our proposal will generate data that identifies functional and structural changes in the
cardiovascular system that occur in during ageing. Using a longitudinal design, this research
will provide high quality evidence that distinguishes healthy from unhealthy cardiovascular
ageing, and reveal determinants and impact of CV ageing over time on CVD and associated
health outcomes.
